Harmony Biosciences Holdings Inc
Slēgts
SektorsVeselības aprūpe
33.78 -0.82
Pārskats
Akcijas cenas izmaiņa
24h
Min
33.32
Max
34.26
Ienākumi | 10M 32M |
|---|---|
Pārdošana | -28M 215M |
P/E Sektora vidējais | 12.984 49.052 |
EPS | 0.786 |
Peļņas marža | 15.084 |
Darbinieki | 293 |
EBITDA | -2.8M 49M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +44.82% upside |
Nākamie ieņēmumi | 2026. g. 4. aug. |
|---|
Tirgus kapitalizācija | -22M 1.9B |
|---|---|
Iepriekšējā atvēršanas cena | 34.6 |
Iepriekšējā slēgšanas cena | 33.78 |
Ziņu noskaņojums
By Acuity
100%
0%
325 / 342 Rangs Healthcare
Harmony Biosciences Holdings Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
